文献速递临床试验与 GCP流行病学与生物统计

季节性大规模接种R21/Matrix-M疫苗用于疟疾消除(SERVAL):整群随机试验方案

Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial.
PubMed 文献 · Trials · 2025-09-29

该整群随机对照试验在冈比亚东部(低至中度传播)和布基纳法索中部(高强度传播)开展,评估季节性大规模接种R21/Matrix-M疟疾疫苗对疟疾传播和发病的影响。冈比亚30个中等规模村庄和布基纳法索24个村庄按1:1随机分配至干预组或对照组,干预组在2024年5月至7月疟疾传播季前接受每三个月一轮的R21接种,2025年6月接种加强针。主要结局为2024年11月传播高峰期的疟疾患病率。

要点

  • 首个评估季节性大规模接种R21以减少疟疾传播的整群随机试验。
  • 在冈比亚和布基纳法索不同传播强度地区开展,覆盖不同年龄组。
  • 主要结局为2024年11月传播高峰期的疟疾患病率。

核心结论

  • 该试验旨在评估季节性大规模接种R21是否降低冈比亚和布基纳法索的疟疾传播。
  • 若成功,R21季节性大规模接种将成为加速疟疾消除的创新干预措施。

研究设计与样本

  • 多中心、开放标签、整群随机对照试验,在冈比亚东部和布基纳法索中部开展。
  • 冈比亚30个中等规模村庄和布基纳法索24个村庄按1:1随机分配至干预组或对照组。
  • 干预村庄所有符合条件的居民在2024年5月至7月疟疾传播季前接受每三个月一轮的R21接种,2025年6月接种加强针。
  • 主要结局为2024年11月传播高峰期的疟疾患病率。

主要发现

  • 该方案未报告试验结果。
  • 次要结局包括安全性和耐受性、临床疟疾发病率、接种覆盖率与社区接受度、干预成本和成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 主要挑战仍为疫苗犹豫和接种覆盖率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Progress in malaria control has stalled since 2015, highlighting the need for new control tools. The R21/Matrix-M (R21) malaria vaccine, a pre-erythrocytic vaccine recently approved by WHO for small children, may be one of these tools. This trial aims to assess whether seasonal mass vaccination with R21 reduces malaria transmission in The Gambia and Burkina Faso, two countries at the extreme of the transmission spectrum. METHODS: This is a multi-centre open cluster-randomised controlled trial to assess the impact of mass vaccination with R21 on malaria transmission and morbidity. The trial will be implemented in eastern Gambia (low to moderate transmission) and Central Burkina Faso (intense transmission). Thirty medium-sized villages in The Gambia and 24 in Burkina Faso will be randomised (1:1) to either intervention or control arm. All eligible residents in intervention villages will receive R21 vaccinations in three-monthly rounds, from May to July 2024, prior to the malaria transmission season. A booster vaccine dose will be administered the following year, in June 2025. The primary outcome is malaria prevalence at peak transmission (November 2024). Secondary outcomes include safety and tolerability, incidence of clinical malaria, vaccination coverage and community acceptability, cost and cost-effectiveness of the intervention. DISCUSSION: This is the first trial on seasonal mass vaccination aiming at reducing malaria transmission. Strengths of the study include its design as an adequately powered cluster-randomised trial and the inclusion of study sites with differing transmission intensity which will also provide safety and efficacy data for different age groups. Key challenges remain vaccine hesitancy and vaccination coverage. If successful, R21 seasonal mass vaccination will be an innovative intervention to accelerate malaria elimination efforts and reach the goal set in the Global Technical Strategy for malaria 2016-2030. TRIAL REGISTRATION: Clinical trials.gov, NCT06578572. Registered on 27 March 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dabira ED, Natama HM, Jaiteh F, et al. Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial. Trials. 2025. PMID: 41024138. doi:10.1186/s13063-025-09048-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。